Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

doi:10.1007/s00535-013-0824-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

Journal of gastroenterology - 1 Apr 2014

Oze Tsugiko, Hiramatsu Naoki, Yakushijin Takayuki, Miyazaki Masanori, Iio Sadaharu, Oshita Masahide, Hagiwara Hideki, Mita Eiji, Inui Yoshiaki, Hijioka Taizo, Inada Masami, Tamura Shinji, Yoshihara Harumasa, Inoue Atsuo, Imai Yasuharu, Miyagi Takuya, Yoshida Yuichi, Tatsumi Tomohide, Kanto Tatsuya, Kasahara Akinori, Hayashi Norio, Takehara Tetsuo

Abstract excerpt

BACKGROUND: HCV kinetics during treatment demonstrated strong association with the antiviral outcome of patients treated with pegylated interferon (Peg-IFN) plus ribavirin. However, the relationship between HCV kinetics and pre-treatment factors remains unclear. METHODS: Of 547 patients with HCV genotype 1 treated with Peg-IFN alfa-2b plus ribavirin, 401 completed the response-guided therapy and were assessed for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Interferons

Share to Interleukins

Share to Liver Cirrhosis

Share to Polyethylene Glycols

Share to Ribavirin

Source

Open in PubMed

Identifiers

PMID: 23689988
DOI: 10.1007/s00535-013-0824-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.PMID 23689988Read ↗

IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.Semantic proximity Read ↗

IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.Semantic proximity Read ↗

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.Semantic proximity Read ↗

Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms.Semantic proximity Read ↗

The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.Semantic proximity Read ↗

Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.Semantic proximity Read ↗

Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.Semantic proximity Read ↗

Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.Semantic proximity Read ↗

Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.Semantic proximity Read ↗

Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.Semantic proximity Read ↗

Failure to achieve 2-log10 viral decrease in first four weeks of peg-IFNalpha-2b plus ribavirin therapy for chronic hepatitis C with genotype 1b and high viral titer is useful in predicting non-response: evaluation of response-guided therapy.Semantic proximity Read ↗

Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.